8-K
filed May 13, 2024, 7:59 PM ET
ticker FLNA
CIK 0001069530
other
confidence high
sentiment neutral
materiality 0.15
Cassava Sciences stockholders elect three directors, ratify auditor, approve say-on-pay at 2024 annual meeting
FILANA THERAPEUTICS, INC.
- Quorum of ~62% (26,979,468 shares) represented at May 9, 2024 annual meeting.
- Three director nominees elected: Barbier (10.8M for), Robertson (8.9M for), Scannon (10.9M for).
- Ratification of Ernst & Young as auditor approved (26.5M for, 0.4M against).
- Advisory vote on 2023 executive compensation approved (9.4M for, 1.3M against).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
FILANA THERAPEUTICS, INC. shareholders approved Advisory vote on 2023 executive compensation at the 2024-05-09 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2024-05-09
Exact text from the filing
The 2023 executive compensation for the Company’s named executive officers was approved, on a non-binding advisory vote, based upon the following votes: For Against Abstain Broker Non -Vote 9,403,571 1,338,907 526,173 15,710,817
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
FILANA THERAPEUTICS, INC. shareholders approved Election of three nominees to the Board of Directors at the 2024-05-09 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-09
Exact text from the filing
Three (3) nominees for election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes: Director For Withheld Broker Non-Vote Remi Barbier 10,768,599 500,052 15,710,817 Sanford R. Robertson 8,944,665 2,323,986 15,710,817 Patrick J. Scannon, M.D., Ph.D. 10,891,367 377,284 15,710,817
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
FILANA THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-09 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-05-09
Exact text from the filing
The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024, was ratified based upon the following votes: For Against Abstain 26,461,553 380,036 137,879
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.